HIGHLIGHTS
- who: Haiying Ding and colleagues from the Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, ChinaEditor: Giurato Giorgio, University of Salemo have published the research: Cost-effectiveness of PARP inhibitors in malignancies: A systematic review, in the Journal: PLOS ONE of June/14,/2022
- what: The authors aimed at evaluating the cost effectiveness of PARPis in the treatment of malignancies.
- future: Their objectives perspective of the analysis measurement of costs and health outcomes were all clearly elaborated.
SUMMARY
Poly . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.